WHAT IS CLAIMED IS:
1. A stable oral liquid pharmaceutical composition, comprising a therapeutically effective amount of celecoxib, at least one solubiliser, at least one medium chain glyceride, at least one polar solvent, and at least one pharmaceutically acceptable excipient, wherein said composition does not show any precipitation in Fasted-State Simulated Gastric Fluid (FaSSGF) at pH of 2.0, temperature of 37°C ± 0.5°C and under stirring at a speed of 50 rpm, when measured at 60 min.
2. The stable oral liquid pharmaceutical composition of claim l, wherein the composition is essentially free of precipitation inhibitors selected from the group consisting of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (SOLUPLUS®), polyoxyethylene-polyoxypropylene block copolymers, pluronics, polyvinylpyrrolidone, and cellulosic polymers, including hydroxypropyl cellulose and hydroxypropyl methylcellulose.
3. The stable oral liquid pharmaceutical composition of claim 1 or 2, wherein the at least one solubiliser is polyethoxylated castor oil (available as KOLLIPHOR EL®), lauryl macrogolglyceride (available as GELUCIRE® 44/14), or a combination thereof.
4. The stable oral liquid pharmaceutical composition of any one of claims 1-3, wherein the at least one medium chain glyceride is glyceryl tricaprylate/tricaprate (available as CAPTEX® 300), glyceryl monocaprylate (available as CAPMUL® MCM C8), or a combination thereof.
5. The stable oral liquid pharmaceutical composition of any one of claims 1-4, wherein the at least one polar solvent is selected from the group consisting of propylene glycol, polyethylene glycols having a molecular weight between 400 and 1000, glycerin, C2 to C8 mono- and poly-alcohols (e.g., ethanol), C7 to C18 alcohols of linear or branched configuration, water and mixtures thereof.

6. The stable oral liquid pharmaceutical composition of any one of claims 1-5, wherein the therapeutically effective amount of celecoxib comprises from about 1% to about 80% celecoxib by weight, based on the total weight of the composition.
7. The stable oral liquid pharmaceutical composition of any one of claims 1-6, wherein the at least one solubiliser is present in an amount of from about 10% to about 70% by weight, based on the total weight of the composition.
8. The stable oral liquid pharmaceutical composition of any one of claims 1-7, wherein a weight ratio of the at least one solubiliser to celecoxib varies from about 4.0: 1.0 to about 20:1.0.
9. The stable oral liquid pharmaceutical composition of any one of claims 1-8, wherein the at least one polar solvent is present in an amount of from about 20% to about 80% by weight, based on the total weight of the composition.
10. The stable oral liquid pharmaceutical composition of any one of claims 1-9, wherein a weight ratio of the at least one solubiliser to the at least one polar solvent varies from about 0.60:1.00 to about 1.8:1.00.
11. The stable oral liquid pharmaceutical composition of any one of claims 1-10, wherein the at least one medium chain glyceride is present in an amount of from about 5% to about 75% by weight, based on the total weight of the composition.
12. The stable oral liquid pharmaceutical composition of any one of claims 1-11, wherein the composition has a mean oil droplet size of not more than 500 nm, when tested in 250 ml of Fasted-State Simulated Gastric Fluid (FaSSGF) at pH of 2.0, temperature of 37°C ± 0.5 °C and under stirring at a speed of 50 rpm.
13. The stable oral liquid pharmaceutical composition of any one of claims 1-12, wherein the composition has a viscosity of from about 20 cps to about 1000 cps.

14. The stable oral liquid pharmaceutical composition of any one of claims 1-13, wherein the composition has a density of from about 0.8 gm/cm3 to about 2 gm/cm3.
15. The stable oral liquid pharmaceutical composition of any one of claims 1-14, wherein the composition has a transmittance of at least 40%.
16. The stable oral liquid pharmaceutical composition of any one of claims 1-15, wherein the composition has apH of from about 3 to about 7.
17. The stable oral liquid pharmaceutical composition of any one of claims 1-16, wherein the therapeutically effect amount of celecoxib is at least about 40% less than conventional celecoxib compositions such as CELEBREX® 400 mg oral capsules.
18. The stable oral liquid pharmaceutical composition of claim 17, wherein the therapeutically effect amount of celecoxib is about 240 mg.
19. The stable oral liquid pharmaceutical composition of any one of claims 1-16, wherein the therapeutically effect amount of celecoxib is at least about 55% less than conventional celecoxib compositions such as CELEBREX® 400 mg oral capsules.
20. The stable oral liquid pharmaceutical composition of claim 19, wherein the therapeutically effect amount of celecoxib is about 180 mg.
21. The stable oral liquid pharmaceutical composition of any one of claims 1-16, wherein the therapeutically effect amount of celecoxib is at least about 70% less than conventional celecoxib compositions such as CELEBREX® 400 mg oral capsules.
22. The stable oral liquid pharmaceutical composition of claim 21, wherein the therapeutically effect amount of celecoxib is about 120 mg.
23. The stable oral liquid pharmaceutical composition of any one of claims 1-22, which upon oral administration to a human subject under fasting conditions, provides at least one of the following pharmacokinetic parameters:

AUC(o-i5min) from about 10 ng.h/mL to about 80 ng.h/mL;
AUC(o-30min) from about 80 ng.h/mL to about 400 ng.h/mL;
AUC (o-ihr, from about 400 ng.h/mL to about 1500 ng.h/mL;
AUC (o-2hr) from about 1000 ng.h/mL to about 4000 ng.h/mL;
AUC(o -t) of at least about 2000 ng.h/mL;
AUC (o-oo, of at least about 2000 ng.h/mL; and
nag of not more than 8 minutes.
24. The stable oral liquid pharmaceutical composition of any one of claims 1-23,
wherein the composition comprises:
a) a therapeutically effective amount of celecoxib;
b) at least one pharmaceutically acceptable excipient;
c) at least one solubiliser in an amount from about 35% w/w to about 45% w/w; and
d) at least one polar solvent in an amount from about 25% w/w to about 42% w/w, wherein the solubiliser and polar solvent are present in a ratio of from about 0.60: 1 to
about 1.8:1; and wherein the stable oral liquid pharmaceutical composition has a viscosity of from about 20 cps to about 1000 cps, and a density of from about 0.8 gm/cm to about 2 gm/cm .
25. A stable oral liquid pharmaceutical composition, comprising from about 100
mg to 250 mg of celecoxib, at least one pharmaceutically acceptable excipient, at least one
solubiliser, at least one medium chain glyceride, and at least one polar solvent, wherein the
composition:
a) releases no less than about 70% of the celecoxib at a period of 10 minutes; or
b) releases no less than about 80% of the celecoxib at a period of 15 minutes,
in 900 ml of 0.0 IN HC1 with 0.5% sodium lauryl sulfate, when tested in a USP Type 2 apparatus with sinkers at 50 rpm and 37°C.
26. The stable oral liquid pharmaceutical composition of claim 25, wherein the
composition is essentially free of precipitation inhibitors selected from the group consisting
of polyvinyl caprolactam-poly vinyl acetate-polyethylene glycol graft copolymer
(SOLUPLUS®), polyoxyethylene-polyoxypropylene block copolymers, pluronics,

polyvinylpyrrolidone, and cellulosic polymers, including hydroxypropyl cellulose and hydroxypropyl methylcellulose.
27. The stable oral liquid pharmaceutical composition of claim 25 or 26, wherein the at least one solubiliser is polyethoxylated castor oil (available as KOLLIPHOR EL®), lauryl macrogolglyceride (available as GELUCIRE® 44/14), or a combination thereof.
28. The stable oral liquid pharmaceutical composition of any one of claims 25-27, wherein the at least one medium chain glyceride is glyceryl tricaprylate/tricaprate (available as CAPTEX® 300), glyceryl monocaprylate (available as CAPMUL® MCM C8), or a combination thereof.
29. The stable oral liquid pharmaceutical composition of any one of claims 25-28, wherein the at least one polar solvent is selected from the group consisting of propylene glycol, polyethylene glycols having a molecular weight between 400 and 1000, glycerin, C2 to C8 mono- and poly-alcohols (e.g., ethanol), C7 to C18 alcohols of linear or branched configuration, water and mixtures thereof.
30. The stable oral liquid pharmaceutical composition of any one of claims 25-29, wherein the therapeutically effective amount of celecoxib comprises from about 1% to about 80% celecoxib by weight, based on the total weight of the composition.
31. The stable oral liquid pharmaceutical composition of any one of claims 25-30, wherein the at least one solubiliser is present in an amount of from about 10% to about 70% by weight, based on the total weight of the composition.
32. The stable oral liquid pharmaceutical composition of any one of claims 25-31, wherein a weight ratio of the at least one solubiliser to celecoxib varies from about 4.0: 1.0 to about 20:1.0.

33. The stable oral liquid pharmaceutical composition of any one of claims 25-32, wherein the at least one polar solvent is present in an amount of from about 20% to about 80% by weight, based on the total weight of the composition.
34. The stable oral liquid pharmaceutical composition of any one of claims 25-33, wherein a weight ratio of the at least one solubiliser to the at least one polar solvent varies from about 0.60:1.00 to about 1.8:1.00.
35. The stable oral liquid pharmaceutical composition of any one of claims 25-34, wherein the at least one medium chain glyceride is present in an amount of from about 5% to about 75% by weight, based on the total weight of the composition.
36. The stable oral liquid pharmaceutical composition of any one of claims 25-35, wherein the composition has a mean oil droplet size of not more than 500 nm, when tested in 250 ml of Fasted-State Simulated Gastric Fluid (FaSSGF) at pH of 2.0, temperature of 37°C ± 0.5 °C and under stirring at a speed of 50 rpm.
37. The stable oral liquid pharmaceutical composition of any one of claims 25-36, wherein the composition has a viscosity of from about 20 cps to about 1000 cps.
38. The stable oral liquid pharmaceutical composition of any one of claims 25-37, wherein the composition has a density of from about 0.8 gm/cm3 to about 2 gm/cm3.
39. The stable oral liquid pharmaceutical composition of any one of claims 25-38, wherein the composition has a transmittance of at least 40%.
40. The stable oral liquid pharmaceutical composition of any one of claims 25-39, wherein the composition has apH of from about 3 to about 7.
41. The stable oral liquid pharmaceutical composition of any one of claims 25-40, which upon oral administration to a human subject under fasting conditions, provides at least one of the following pharmacokinetic parameters:
AUC(o-i5min) from about 10 ng.h/mL to about 80 ng.h/mL;

AUC(o-30min) from about 80 ng.h/mL to about 400 ng.h/mL;
AUC (O-ihr, from about 400 ng.h/mL to about 1500 ng.h/mL;
AUC (o-2hr) from about 1000 ng.h/mL to about 4000 ng.h/mL;
AUC(o-t) of at least about 2000 ng.h/mL;
AUC /o-oOj of at least about 2000 ng.h/mL; and
Tiag of not more than 8 minutes.
42. The stable oral liquid pharmaceutical composition of any one of claims 25-4 1,
wherein the composition comprises:
e) a therapeutically effective amount ofcelecoxib;
f) at least one pharmaceutically acceptable excipient;
g) at least one solubiliser in an amount from about 35% w/w to about 45% w/w; and h) at least one polar solvent in an amount from about 25% w/w to about 42% w/w, wherein the solubiliser and polar solvent are present in a ratio of from about 0.60: 1 to
about 1.8: 1; and wherein the stable oral liquid pharmaceutical composition has a viscosity of from about 20 cps to about 1000 cps, and a density of from about 0.8 gm/cm to about 2 gm/cm .
43. Use of a stable oral liquid pharmaceutical composition according to any one of claims 1-42 for the treatment of pain in a subject.
44. The use of claim 43, wherein the stable oral liquid pharmaceutical composition comprises a therapeutically effective amount of celecoxib, at least one solubiliser in amount from about 35 % w/w to about 45 % w/w, at least one polar solvent in amount from about 25 % w/w to about 42 % w/w, at least one medium chain glyceride, and at least one pharmaceutically acceptable excipient, wherein the stable oral liquid pharmaceutical composition is essentially free of precipitation inhibitors.
45. The use of claim 43 or 44, wherein the pain is associated with migraine.

46. The use of any one of claims 43-45, wherein the therapeutically effective amount of celecoxib is sufficient to render the subject pain free within 2 hours of administering the stable oral liquid pharmaceutical composition.
47. The use of any one of claims 43-46, wherein the therapeutically effective amount of celecoxib is sufficient to lead to partial pain relief in the subject within 2 hours of administering the stable oral liquid pharmaceutical composition.
48. The use of any one of claims 43-47, wherein administering the stable oral liquid pharmaceutical composition leads to pain free at 2 hours in at least 25% of the human subjects being treated.
49. The use of any one of claims 43-48, wherein administering the stable oral liquid pharmaceutical composition leads to partial pain relief at 2 hours in at least 45% of the human subjects being treated.
50. The use of any one of claims 43-49, wherein administering the stable oral liquid pharmaceutical composition leads to an increase in the percentage of human subjects being treated being pain free at 2 hours that is at least 40% in comparison to the percentage of human subjects being treated with a placebo.
51. The use of any one of claims 43-50, wherein administering the stable oral liquid pharmaceutical composition leads to an increase in the percentage of human subjects being treated being partially relieved of pain at 2 hours that is at least 10% in comparison to the percentage of human subjects being treated with a placebo.
52. The use of any one of claims 43-51, wherein administering the stable oral liquid pharmaceutical composition leads to an increase in the percentage of human subjects being treated being pain free at 2 hours that is at least 10% in comparison to the percentage of human subjects being treated with a commercially available migraine pain treatment, such as VIOXX 25 (25 mg), VIOXX 50 (50 mg) and CAMBIA 50 (50 mg).

53. The use of any one of claims 43-52, wherein administering the stable oral liquid pharmaceutical composition leads to an increase in the percentage of human subjects being treated being partially relieved of pain at 2 hours that is at least 10% in comparison to the percentage of human subjects being treated with a commercially available migraine pain treatment, such as VIOXX 25 (25 mg), VIOXX 50 (50 mg) and CAMBIA 50 (50 mg).
54. A stable oral liquid pharmaceutical composition of celecoxib comprising
i. therapeutically effective amount of celecoxib, at least one solubiliser, at least
one medium chain glyceride; and ii. polar solvent comprising mixture of ethanol and glycerin; wherein the composition falls within the shaded region of a phase diagram, as shown in Figure, l, wherein boundaries of a stable composition are defined by shaded region or the region between the connecting lines between the six points (a, b, c, d , e and f), wherein the composition comprises about 1% to about 80% w/w celecoxib and correspond to a weight % ratio of base composition : ethanol: glycerin of 0.200:0.024:0.712 for a, 0.200:0.376:0.360 for b, 0.200:0.400:0.336 for c, 0.536:0.400:0.000 for d, 0.900:0.036:0.00 for e, and 0.900:0.00:0.036 for f.
55. The stable oral liquid pharmaceutical composition of claim 54, wherein said therapeutically effective amount of celecoxib is at least 40% less compared to conventional celecoxib compositions such as CELEBREX® 400 mg oral capsules.
56. The stable oral liquid pharmaceutical composition of claim 55, wherein the therapeutically effect amount of celecoxib is about 240 mg.
57. The stable oral liquid pharmaceutical composition of claim 54, wherein the therapeutically effect amount of celecoxib is at least about 55% less than conventional celecoxib compositions such as CELEBREX® 400 mg oral capsules.
58. The stable oral liquid pharmaceutical composition of claim 57, wherein the therapeutically effect amount of celecoxib is about 180 mg.

59. The stable oral liquid pharmaceutical composition of claim 54, wherein the therapeutically effect amount of celecoxib is at least about 70% less than conventional celecoxib compositions such as CELEBREX® 400 mg oral capsules.
60. The stable oral liquid pharmaceutical composition of claim 59, wherein the therapeutically effect amount of celecoxib is about 120 mg.
61. The stable oral liquid pharmaceutical composition of any one of claims 54-60, which upon oral administration to a human subject under fasting conditions, provides at least one of the following pharmacokinetic parameters:
AUC(o-i5min) from about 10 ng.h/mL to about 80 ng.h/mL;
AUC(o-30min) from about 80 ng.h/mL to about 400 ng.h/mL;
AUC (o-ihr, from about 400 ng.h/mL to about 1500 ng.h/mL;
AUC (o-2hr) from about 1000 ng.h/mL to about 4000 ng.h/mL;
AUC(o -t) of at least about 2000 ng.h/mL;
AUC (o-oo, of at least about 2000 ng.h/mL; and
nag of not more than 8 minutes.
62. The stable oral liquid pharmaceutical composition of any one of claims 54-6 1,
wherein the composition comprises:
i) a therapeutically effective amount of celecoxib; j) at least one pharmaceutically acceptable excipient;
k) at least one solubiliser in an amount from about 35% w/w to about 45% w/w; and l) at least one polar solvent in an amount from about 25% w/w to about 42% w/w, wherein the solubiliser and polar solvent are present in a ratio of from about 0.60: 1 to about 1.8:1; and wherein the stable oral liquid pharmaceutical composition has a viscosity of from about 20 cps to about 1000 cps, and a density of from about 0.8 gm/cm to about 2 gm/cm .
63. The stable oral liquid pharmaceutical composition of any one of claims 54-62,
wherein said composition does not show any precipitation in Fasted-State Simulated Gastric

Fluid (FaSSGF) at pH of 2.0, temperature of 37°C ± 0.5°C and under stirring at a speed of 50 rpm, when measured at 60 min.
64. The stable oral liquid pharmaceutical composition of any one of claims 54-63, wherein the composition is essentially free of precipitation inhibitors selected from the group consisting of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (SOLUPLUS®), polyoxyethylene-polyoxypropylene block copolymers, pluronics, polyvinylpyrrolidone, and cellulosic polymers, including hydroxypropyl cellulose and hydroxypropyl methylcellulose.
65. The stable oral liquid pharmaceutical composition of any one of claims 54-64, wherein the at least one solubiliser is polyethoxylated castor oil (available as KOLLIPHOR EL®), lauryl macrogolglyceride (available as GELUCIRE® 44/14), or a combination thereof.
66. The stable oral liquid pharmaceutical composition of any one of claims 54-65, wherein the at least one medium chain glyceride is glyceryl tricaprylate/tricaprate (available as CAPTEX® 300), glyceryl monocaprylate (available as CAPMUL® MCM C8), or a combination thereof.
67. The stable oral liquid pharmaceutical composition of any one of claims 54-66, wherein the at least one polar solvent is selected from the group consisting of propylene glycol, polyethylene glycols having a molecular weight between 400 and 1000, glycerin, C2 to C8 mono- and poly-alcohols (e.g., ethanol), C7 to C18 alcohols of linear or branched configuration, water and mixtures thereof.
68. The stable oral liquid pharmaceutical composition of any one of claims 54-67, wherein the therapeutically effective amount of celecoxib comprises from about 1% to about 80% celecoxib by weight, based on the total weight of the composition.
69. The stable oral liquid pharmaceutical composition of any one of claims 54-68, wherein the at least one solubiliser is present in an amount of from about 10% to about 70% by weight, based on the total weight of the composition.

70. The stable oral liquid pharmaceutical composition of any one of claims 54-69, wherein a weight ratio of the at least one solubiliser to celecoxib varies from about 4.0: 1.0 to about 20:1.0.
71. The stable oral liquid pharmaceutical composition of any one of claims 54-70, wherein the at least one polar solvent is present in an amount of from about 20% to about 80% by weight, based on the total weight of the composition.
72. The stable oral liquid pharmaceutical composition of any one of claims 54-71, wherein a weight ratio of the at least one solubiliser to the at least one polar solvent varies from about 0.60:1.00 to about 1.8:1.00.
73. The stable oral liquid pharmaceutical composition of any one of claims 54-72, wherein the at least one medium chain glyceride is present in an amount of from about 5% to about 75% by weight, based on the total weight of the composition.
74. The stable oral liquid pharmaceutical composition of any one of claims 54-73, wherein the composition has a mean oil droplet size of not more than 500 nm, when tested in 250 ml of Fasted-State Simulated Gastric Fluid (FaSSGF) at pH of 2.0, temperature of 37°C ± 0.5 °C and under stirring at a speed of 50 rpm.
75. The stable oral liquid pharmaceutical composition of any one of claims 54-74, wherein the composition has a viscosity of from about 20 cps to about 1000 cps.
76. The stable oral liquid pharmaceutical composition of any one of claims 54-75, wherein the composition has a density of from about 0.8 gm/cm3 to about 2 gm/cm3.
77. The stable oral liquid pharmaceutical composition of any one of claims 54-76, wherein the composition has a transmittance of at least 40%.
78. The stable oral liquid pharmaceutical composition of any one of claims 54-77, wherein the composition has apH of from about 3 to about 7.